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Abstract The International Society for Strategic Studies in
Radiology held its 9th biennial meeting in August 2011. The
focus of the programme was integrated diagnostics and mas-
sive computing. Participants discussed the opportunities, chal-
lenges, and consequences for the discipline of radiology that
will likely arise from the integration of diagnostic technolo-
gies. Diagnostic technologies are increasing in scope, includ-
ing advanced imaging techniques, new molecular imaging
agents, and sophisticated point-of-use devices. Advanced in-
formation technology (IT), which is increasingly influencing
the practice of medicine, will aid clinical communication and
the development of “population images” that represent the
phenotype of particular diseases, which will aid the develop-
ment of diagnostic algorithms. Integrated diagnostics offer
increased operational efficiency and benefits to patients
through quicker and more accurate diagnoses. As physicians
with the most expertise in IT, radiologists are well placed to
take the lead in introducing IT solutions and cloud computing
to promote integrated diagnostics. To achieve this, radiologists
must adapt to include quantitative data on biomarkers in their
reports. Radiologists must also increase their role as partici-
pating physicians, collaborating with other medical special-
ties, not only to avoid being sidelined by other specialties but
also to better prepare as leaders in the selection and sequence
of diagnostic procedures.
Key Points
• New diagnostic technologies are yielding unprecedented
amounts of diagnostic information.
• Advanced IT/cloud computing will aid integration and
analysis of diagnostic data.
• Better diagnostic algorithms will lead to faster diagnosis
and more rapid treatment.
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Introduction
Making medicine more personalised and precise will entail
increasing emphasis on, and precision in, diagnostics. To
date, experience and intuition have been physicians’ prima-
ry tools for integrating clinical information and test results
into a diagnosis. However, new diagnostic technologies,
along with high-throughput technologies for biomedical
analysis, are now yielding unprecedented amounts of data
reflecting not only anatomy and pathology, but molecular
processes and genetics as well [1]. Scientists continually
report new subtypes as well as new genetic, serum, and
tissue biomarkers of disease [1, 2]. With time, data overload
is only going to increase [3]. The unassisted human mind
cannot make optimal use of this avalanche of information
either in the clinic or for research. What is required is a new
concept of “integrated diagnostics”: the convergence of
imaging, pathology, and laboratory tests with advanced
information technology (IT).
Making the most of available data and resources has
never been more critical. Around the world, pressures are
mounting to expand healthcare coverage while reducing its
cost. In the USA, for instance, where millions of individuals
remain uninsured, healthcare costs account for nearly $1 of
every $5 of national income and are considered a major
obstacle to economic recovery and long-term growth [4,
5]. Much of the spending is wasteful—the result of
inappropriate or fragmented care, in which diagnostic tests
and treatments are underused, overused, or delayed. It is
clear that flaws in processes such as communication and
coordination [6], as well as gaps in medical knowledge, are
obstructing the path to personalised medicine, in which the
right treatment is delivered to the right patient at the right
time. High rates of medically preventable deaths have been
observed in the USA as well as other developed countries,
including the UK, Denmark, and Australia [4, 7]. In the
USA alone, it is estimated some 40,000 to 80,000 patients
die as a result of missed diagnoses while approximately
100,000 die from non-error adverse drug effects each year
[8, 9]. More appropriate use of existing diagnostics, as well
as the development of better diagnostics, could prevent
incorrect and delayed diagnoses and enable more appropri-
ate treatments with lower costs and better outcomes.
Recent studies suggest that integrated delivery systems,
in which specialists share information and work in teams to
determine which tests and procedures are necessary, result in
less costly, higher-quality care [10, 11]. By providing rapid
access to patient data and decision support tools, clinical IT
can play an essential role in integrating healthcare services
[6]. Furthermore, widespread implementation of advanced
IT in research and clinical settings could hasten the valida-
tion and application of new disease biomarkers and diag-
nostic algorithms.
This article considers some of the many ways that inte-
grated diagnostics with advanced IT could increase the
quality and efficiency of healthcare—and perhaps even fa-
cilitate a paradigm shift from curative to preventive medi-
cine. Special attention is given not only to the importance of
imaging in unravelling the links between various types of
diagnostic data, but to radiologists’ future role in the prac-
tice of integrated diagnostics.
Paradigm-changing diagnostic technologies
The gradual shift toward precision medicine now underway
has been driven by rapid growth in diagnostics. Radiology
has seen enormous growth in imaging utilisation [12] as
well as the development of new imaging techniques that
provide functional as well as anatomical information [13].
Automated machines in centralised laboratory facilities turn
out ever-increasing amounts of genetic and molecular bio-
marker data [14, 15], while pathology laboratories perform
ever-escalating numbers of semi-automated immunohisto-
chemical assays [15].
In the future, new, easy-to-use, miniaturised diagnostic
“lab-on-a-chip” devices that employ nanomaterials, micro-
arrays, and microfluidics will likely cause the volume of
diagnostic data to grow even more rapidly [16]. The
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combination of these miniaturised devices with novel imag-
ing techniques and more conventional diagnostic techniques
may change diagnostic paradigms.
Magnetic nanoparticle-based point-of-care diagnostic
technology
Some of the most exciting developments in diagnostic tech-
nology include a new class of miniaturised devices that
depend on magnetic nanoparticle (MNP) tags carrying anti-
bodies to biomarker proteins [17, 18]. Since biological
samples lack any detectable magnetic signal and magnetic
properties are not affected by turbidity or sample impurities,
such devices have the capacity to be both highly sensitive
and highly specific.
Two devices that utilise MNP tags are now available, and
both are well suited to point-of-care-diagnostics, as they re-
quire no specialised laboratory facilities or sample prepara-
tion, are inexpensive to use, and can be employed by
personnel with varying levels of education and experience
[19, 20]. One of these devices employs giant magnetoresistive
(GMR) sensors; it can simultaneously measure the concentra-
tion of multiple biomarkers in clinical samples such as urine,
serum, cell lysates, or saliva and is 1,000 times as sensitive as
the current clinical standard, ELISA [17]. The other such
device uses miniaturised nuclear magnetic resonance techno-
logy to analyse unprocessed biological samples and detect
biomarkers on cells as well as in biological fluids; it can
simultaneously and rapidly test for multiple biomarkers [20]
with an accuracy that may exceed that of conventional cyto-
logy [21]
Molecular imaging
Over the past decade, molecular imaging has been hailed as
the future of radiology [22]. Although most molecular im-
aging studies are still performed in animals, there is opti-
mism that more of these imaging techniques will soon be
adopted clinically. For example, there are new imaging
techniques, such as hyperpolarized 13C MRI [23], many
promising new PET tracers for diseases including cancer
and Alzheimer’s disease [24], and some novel multimodal
contrast agents [25, 26].
Metabolic imaging with hyperpolarized 13C MRI is more
than 10,000 times more sensitive than 1H magnetic reso-
nance spectroscopy (MRS) and promises to be a valuable
clinical technique. The technique has detected changes
corresponding to tumour response within 1 day of initiation
of treatment and is now being used to explore pyruvate
metabolism in human prostate cancer [23]. Hyperpolarized
13C-pyruvate MRI could be particularly valuable in the
brain, where the rapid rate of glucose metabolism precludes
the use of FDG-PET to detect response to treatment [27].
Promising new multimodal contrast agents now under
investigation include MRI–Raman–photoacoustic nanopar-
ticles [25] and C-Dots [26]. MRI–Raman–photoacoustic
nanoparticles combine sensitivity, specificity, resolution,
and depth. Detection of these nanoparticles by MRI is
valuable for presurgical planning and intraoperative guid-
ance. The gold layer delivers a photoacoustic signal, which
is also useful in intraoperative imaging and amplifies the
Raman signal, enabling highly sensitive optical detection of
the tumour and its complete removal with clean margins, as
has been demonstrated in mouse models [25].
C-Dots, small enough (7 nm) to be cleared by the renal
system, are radiolabelled agents functionalised to target
specific tumour antigens. Theses agents, detectable with
both optical technology and PET and in real time using
handheld intraoperative tools, are now in an FDA-
approved trial [26].
Novel imaging techniques
Diagnostic accuracy will also be improved by using acoustic
radiation force impulse (ARFI) imaging and by the addition
of optics to catheters and needles. ARFI is a recently devel-
oped technique that has been shown to aid ultrasound visu-
alization of needle placement, providing accurate
positioning that can be used to guide biopsies in interven-
tional radiology [28]. Optical fibres have been developed
that are small enough to reach the coronary arteries via
catheters to allow direct examination of arteries for athero-
sclerotic plaque. In animals, these fibres have been
employed in catheters to provide co-localised information
on microstructure and molecular function in coronary arter-
ies, using near-infrared fluorescence and frequency domain
imaging [29], or to visualise bile duct anatomy during
surgery [30]. Optical catheters and endoscopes can be used
to discriminate between normal, precancerous, and malig-
nant tissue by measuring autofluorescence [31] and could be
useful for surgical tumour margin assessment, for biopsy
guidance in superficial tumours (such as breast and prostate
cancers), and for therapy response monitoring. Other optical
catheters use Raman spectroscopy to interrogate arteries,
generating an endoluminal map of the deposition of choles-
terol, triglycerides, and other plaque components [32].
These technologies, when they become clinically available,
will be able to provide real-time diagnostic information [33].
Future diagnostic algorithms
Not all of the new diagnostic techniques discussed above
involve imaging, but many cross the lines between
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traditional specialties. Optimal employment of these techni-
ques will likely require new paradigms for diagnosis. At
present, the typical diagnostic journey (Fig. 1) starts with a
referral to a specialist, who reviews the patient’s symptoms
and orders one or more tests [34]. If those prove negative,
the patient is referred to a second specialist, who again goes
through the process of reviewing symptoms and ordering
tests. This iterative process may be repeated multiple times
before a positive diagnosis is reached. Worse, the patient
may be treated without having received an accurate diagno-
sis, which fails to help the patient and wastes both time and
resources.
A future diagnostic algorithm could start in the prima-
ry care physician’s office, using a handheld device to
measure diagnostic biomarkers for diseases, such as can-
cer. If the results are positive, the patient could then be
sent for molecular whole-body imaging to identify the
site(s) of disease. Then after fine-needle biopsy of the
tumour, μNMR could be used to identify the presence of
specific tumour antigens, which would confirm the diag-
nosis and guide the selection of treatment. Finally, if
surgical resection is appropriate, multimodal contrast
agents could be used for presurgical planning and intra-
operative imaging to ensure the complete removal of the
tumour [25].
The future of molecular imaging and other novel diag-
nostic techniques will depend on close cooperation among
those who develop the techniques, regulatory bodies, and
industry and will need wide acceptance by the pharmaceu-
tical industry. Furthermore, radiologists need to be part of a
business model, together with others responsible for diag-
nostics, to drive the success of personalized medicine and
integrated diagnostics.
The avalanche of data that existing and new diagnostic
technologies generate can provide the information needed
for rapid and accurate diagnosis. However, algorithms must
be developed that optimize the selection of diagnostic meth-
ods and the order in which they are applied to achieve
optimal speed and cost efficiency in diagnosis. The accu-
mulated diagnostic data must be synthesised and analysed—
a complex and challenging process likely to require collab-
oration among medical specialists and the implementation
of sophisticated IT tools [35].
The importance of advanced IT for integrated
diagnostics
Achieving cost-effective, evidence-based use of diagnostics
requires balancing many factors, including the negative and
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Fig. 1 Schematic of the current diagnostic algorithm for many patients. Courtesy of Gene Saragnese, MD, Philips Healthcare, Andover, MA
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positive predictive values of available tests, the costs and
risks associated with them, and the age and clinical history
of the individual patient, to name just a few. As more
diagnostic tests become available, the difficulty of weighing
these factors only grows [36]. Advanced IT tools for data
sharing, data mining, statistical modelling, and clinical de-
cision support can not only prevent basic medical errors due
to poor communication of information, they can help inte-
grate and analyse complex data to clarify what test should be
applied when, based on evidence rather than intuition or
habit [36, 37].
Clinical test results make up a clinical phenotype of
disease expression, while imaging biomarkers make up an
imaging phenotype, and so forth. By finding links between
the various phenotypes as well as patient and disease geno-
types, it is possible to increase diagnostic speed and preci-
sion and unravel biological mechanisms of disease [38].
Thanks to the digitisation of biomedical data, bioinformatics
is becoming an increasingly powerful tool for this purpose.
Bioinformatics involves the use of computational techni-
ques in pattern recognition, data mining, machine learning,
visualization, and other applications to analyse and identify
connections between various types of biomedical data [38].
Computerised data mining can be done in a “structured”
fashion, in which the computer searches for features or
patterns initially selected by the human operator, or in an
“unstructured” fashion, in which the computer identifies
patterns on its own. In the structured approach, the human-
identified features are subjected to hypothesis testing not by
creating new prospective experiments, but by extensively
searching data derived from prior experiments [38].
Naturally, the larger the database used, the greater the like-
lihood of identifying meaningful patterns and correlations
although the computing demands are high. Cloud comput-
ing may provide a solution.
Cloud computing
Cloud computing is, essentially, the use of servers on a
network to provide rapid, secure, remote access to shared
computer resources (data storage, applications, or other
computer services) [39, 40]. It allows users to store and
utilise much greater volumes of data, at a much lower cost,
than they could locally. It also enables them to access their
data and applications from anywhere, anytime via the Web.
Data can be shared across institutions, platforms, and appli-
cations. In addition, cloud computing supports high-
performance computing, in which large quantities of data
are analysed through parallel processing on multiple com-
puters [41, 42].
Cloud computing is increasingly penetrating every corner
of daily life. To find an example of it, one must look no
further than the popular messaging and collaboration
applications offered by Google, such as Gmail, Google
Calendar, and Google Docs. With such applications, users
can send e-mail, store, access, and share documents, and
update their calendars from stationary computers or mobile
handheld devices without purchasing any additional hard-
ware or software [43].
Health information exchanges
Cloud computing as well as remotely accessible internal
organisational networks are increasingly being used to make
accessing and integrating medical data easier. For example, at
the University of California Los Angeles, the Radiology–
Pathology project is developing a concise, electronic Web-
based report that combines clinically pertinent imaging and
pathologic diagnostic information; physicians will be able to
access the report securely through theWeb evenwhen they are
away from their primary practice locations [44]. In the USA,
at least 196 health information exchanges have been created,
through which patient data are exchanged between facilities
within a hospital system, community, or region [45]. With
support from the National Institute of Biomedical Imaging
and Bioengineering (NIBIB), the Radiological Society of
North America is piloting a patient-centred secure image-
sharing network that relies on cloud computing [46].
Furthermore, Google, Microsoft, and several other companies
have launched cloud-based personally controlled health
records (PCHR) systems [47] that allow patients to store,
access, and share their healthcare records on the Web, using
password protection comparable to that found on online bank-
ing sites. With PCHR systems such as Google Health and
Microsoft HealthVault, individuals may grant access to their
information to care providers, family members, or others—
including researchers [47].
At the most basic level, systems such as health informa-
tion exchanges and PCHRs facilitate integrated diagnostics
by enabling physicians to rapidly assemble patients’ health
records and test results, regardless of where or when they
were originally obtained. The resulting improvements in
communication are expected to reduce medical errors and
increase healthcare quality, safety, and efficiency [48].
In the longer term, cloud-based systems for sharing pa-
tient data could also have a tremendous impact on research
into new diagnostic, treatment, and preventive methods.
Today, researchers are usually only able to study patients
from their own institutions. However, widespread adoption
of PCHRs, for example, could make it possible for research-
ers to quickly and affordably recruit patients from other
academic and community healthcare centres, even from
other countries [47]. In addition, research institutions may
themselves share large amounts of data through cloud com-
puting. The resulting, potentially “global” study cohorts
could dwarf those of even the largest of today’s multicentre
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studies, dramatically expanding the possibilities for popula-
tion studies and the power of bioinformatics analyses.
By evaluating large, well-defined population samples
over extended periods of time, population studies allow
researchers to better separate the effects of environment,
lifestyle, genetics, and other factors on disease development
and long-term health outcomes. For example, the ongoing
Rotterdam Study, initiated at Erasmus University in 1990,
assesses factors influencing the development of chronic
diseases in a large cohort of subjects enrolled at age 45 years
or more; participants are interviewed at baseline and peri-
odic follow-up visits, are examined in the study centre,
undergo imaging, and have bodily fluids collected for mo-
lecular and genetic analyses [49]. The Rotterdam Study has
identified numerous associations between lifestyle, clinical,
molecular, and genetic variables and common chronic dis-
eases. In 2005, an MR imaging unit was added to the
Rotterdam Study enabling the identification of correlations
between imaging biomarkers (imaging phenotypes), clinical
phenotypes, and genotypes. Through this process, the value
of imaging biomarkers in predicting disease can be estab-
lished and validated. By 2009, the Rotterdam Study had a
population of approximately 15,000 and had resulted in
nearly 1,000 research articles and reports [49].
Population imaging
Bioinformatics is already affecting radiology and will push
radiology into becoming more information rich. This tran-
sition will accelerate with increasing use of population im-
aging—the large-scale acquisition and analysis of images in
controlled patient cohorts. Population imaging employs
computational radiology techniques such as unstructured
and structured data mining, image segmentation, and statis-
tical modelling to map and summarise imaging features
from large image databases and thus extract meaningful
imaging biomarkers [38]. The biomarkers may be anatomic
structures, disease manifestations, tumour characteristics, or
haemodynamic abnormalities.
The summation of one or more imaging features, or
biomarkers, from a global data set can be considered a
phenotypic “population image” representing a particular
disease or health state. In clinical care or clinical trials,
population images may be used as a reference to classify
individuals or patient groups into diagnostic categories [38,
50, 51]. Radiologists can play a key leadership role in
providing the needed intuition to productively integrate the
computational information from population images with
personal medical information [38].
Digital imaging techniques have enabled the develop-
ment of new methods for automating and increasing
throughput of image processing, allowing faster, more pre-
cise visualisation and quantification of imaging findings and
thus facilitating population imaging studies [50, 51].
Though expensive, non-invasive digital MRI is particularly
valuable for assessing chronic disease longitudinally, as it
can be done serially, starting before the onset of disease, and
can provide information on multiple levels, anatomic, met-
abolic, and functional. As part of the Rotterdam Study [49],
population imaging with MRI has been used to examine the
causes and consequences of brain changes over time. Using
automated image segmentation and other computational
radiology techniques, the investigators identified numerous
relationships between quantitative and qualitative imaging
features and clinical, pathologic, laboratory, and genetic
findings related to stroke risk and the development of de-
mentia [50].
These imaging biomarkers may facilitate prediction of
future disease onset, the development and implementation
of preventive measures, and even the development of pre-
clinical diagnostics. Biomarkers derived from population
studies may also be used to detect and characterise clinically
apparent disease, guide research into new treatments, and
assess treatment responses in clinical trials and practice [50,
52]. Furthermore, because of the statistical power provided
by large sample sizes, population studies using global data-
bases could potentially replace individual prospective stud-
ies as a means of validating new biomarkers, saving both
time and money [38, 51].
Advanced IT is now making unprecedentedly large-scale
imaging research feasible. For example, cloud computing,
along with high-performance computing, is likely to play an
important role in Euro-BioImaging, a pan-European re-
search infrastructure project that is currently in its prepara-
tory phase. The project is expected to offer platforms for
storing, remotely accessing, and post-processing biological
and medical imaging data on a large scale to enable multi-
national sharing of imaging data, reuse of existing data in
light of new questions, and advanced analysis of imaging
data away from its place of origin [53, 54].
Clinical decision support
Interactive clinical decision support and other computing
tools are now available to help both clinicians and patients
make optimal use of health information. Through PCHRs,
patients may enter their own test results into disease-
management tools [47]. According to Clarient (Aliso
Viejo, USA, a GE Healthcare company), its service
PATHSiTE® allows physicians not only to view high-
resolution digital immunohistochemistry slides along with
detailed interpretive reports, but also to review and analyse
flow cytometry test results, view patients’ complete case
histories, and create tumour board presentations via a secure
Web portal [55, 56]. In another example, the recently intro-
duced platform Qualibria brings together data from an
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organization’s other IT platforms, relevant evidence-based
best practices, and the organization’s own clinical standards
in a single display, according to GE Healthcare (Waukesha,
WI, USA) [56, 57]. Alerts are automatically issued when
variations from desired outcomes are detected. Using the
platform, organizations can share information and incorpo-
rate each other’s best practices [57].
Prediction models for assessing pre- and post-test prob-
abilities of disease are another form of clinical decision
support [37, 58, 59]. Such models can be used to tailor
diagnostic algorithms to individual patients, first by deter-
mining if a particular test is likely to be of value, and then by
incorporating the test result with other variables to assess the
likelihood of the presence, or future development, of disease
[37]. These models, however, are setting specific and do not
necessarily remain applicable as populations change [59,
60]. Theoretically, using high-performance computing in a
cloud, the models, some of which are already on the
Internet, could be automatically updated for specific settings
in real time, whenever new patient data are entered into
electronic medical records systems [37, 58].
Concerns and challenges
Realizing the potential of advanced IT for improving diag-
nostics essentially involves three steps: (1) digitizing med-
ical information and establishing connectivity so that data
can be rapidly accessed and shared; (2) implementing ad-
vanced analytics techniques across data types to change
information overload into insights; and (3) integrating these
insights into healthcare workflow to inform decisions [56].
While other industries, such as banking, have learned to use
advanced IT to aggregate, integrate, and apply large
amounts of digitized data, healthcare is mainly still working
to achieve digitization and connectivity. This is by far the
most financially and culturally challenging stage, and the
benefits will increase with each successive step [56].
Costs are one of the major obstacles to building and
maintaining the infrastructure for advanced IT. Achieving
digitization and connectivity is expensive, though providers,
payers, and patients benefit from the resulting increases in
efficiency [48]. As noted earlier, facilities may minimise IT
costs by sharing infrastructure and other computer resources
through cloud computing. Until recently, health information
exchanges generally relied on centralized management of
data-sharing agreements between individual facilities or
healthcare networks by independent health information
organizations, but “in-house” development of exchange ca-
pabilities is now on the rise [45, 47]. Health information
exchanges in the USA have mainly been funded by grants
and contributions from participating facilities, and few have
become self-sustaining [45, 48]. Notably, of the more suc-
cessful ones, most provide not only data exchange, but
additional tools such as advanced analytics, quality report-
ing, or clinical decision support [45]. There is some debate
as to whether capabilities for electronic exchange of health
information should be funded by those who use them or, as
is the case in the UK, by the government [48]. With PCHR
systems, compared with conventional health information
exchanges, many expenses—along with control of patient
data—are shifted away from healthcare organizations [47].
Concerns about patient privacy and data security are
another considerable hurdle to large-scale data integra-
tion. Doubts about the security of cloud computing
linger, and some healthcare organizations still prefer to
maintain responsibility for data security by containing
their patient data within their own firewalls. In the
USA, laws regarding patient privacy and secure han-
dling of patient information have not been harmonized
across states, and standards have yet to be defined for
locating and matching patient information across health-
care facilities and networks [61]. Particularly with
PCHR systems, data may be shared, wittingly or unwit-
tingly, with entities not bound by HIPAA regulations
[47]. Even when Internet portals are password protected,
sharing of patient data with multiple parties may in-
crease the risk of accidental or deliberate security
breaches. Notably, the Euro-BioImaging infrastructure
project is expected to provide European standards not
only for imaging data storage and analysis, but for data
protection [53].
Finally, particularly when conducting “global” studies
using advanced IT, making sure that data have been
collected and entered consistently, using standardised no-
menclature, is a great challenge. Apart from the fact that
testing protocols, technology, and diagnostic accuracy
typically vary from one setting to another, diagnostic
terminology varies among diagnostic disciplines and
within and between institutions. Tools such as natural
language processing can be used to rapidly analyse
aspects of unstructured reports [62]. However, ultimately,
the goal should be widespread implementation of struc-
tured reporting with standardised terminology. In 2007, to
work toward this goal, nine countries came together to
found the non-profit International Health Terminology
Standards Development Organization (IHTSD) [63]. Its
mission is to acquire, develop, maintain, promote, and
enable the uptake and correct use of standard healthcare
terminology products around the world [63]. Among
other terminologies, the organization administers the
rights to the Systemized Nomenclature of Medicine
Clinical Terms (SNOMED-CT), which is widely consid-
ered the most comprehensive, machine-readable clinical
vocabulary available [63, 64]. The IHTSD has now ex-
panded to include seven other countries. Membership
fees are adjusted on the basis of national income [63].
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The role of radiologists
Integrated diagnostics presents an opportunity for radiology
to evolve as a profession and deepen the impact of the
radiologist on healthcare [34]. Imaging plays a central role
in diagnostics because of its ability to visualize disease in
vivo, to measure its extent and severity anatomically, and to
characterize it functionally and metabolically both in the
context of initial work-up and in response to therapy. As
the practice of medicine moves away from an intuitive,
experience-based model to empirical, evidence-based and
to personalised medicine, diagnostic precision becomes par-
amount in order to select the particular treatment that will
best help each individual patient [36].
Diagnoses depend onmultiple components that include not
only imaging, but also clinical observation, pathology, labo-
ratory, and genomic tests. To date, there is too little coordina-
tion between the medical specialties responsible for ordering
and performing these tests, nor is there enough consideration
as to the optimal order of tests. This will change in a world of
integrated diagnostics, where, instead of relying on individual
provider bias in the selection of tests, data from diverse
sources will be used to determine the most efficient diagnostic
algorithms. Imaging will be incorporated judiciously into
these integrated diagnostic algorithms, complementing other
diagnostic techniques in order to maximise efficiency and
minimise waste. This may satisfy payers who currently per-
ceive radiology as a major contributor to cost escalation. The
American College of Radiology (ACR) has taken some initial
steps towards the development of integrated diagnostics in its
Appropriateness Criteria® [65], which are developed by pan-
els of radiologists and other specialists, by including clinical
symptoms and the results of laboratory tests in determining
imaging appropriateness. Other guidelines have been prepared
in other countries, notably in the UK by the Royal College of
Radiologists and France by the Société Française de
Radiologie; the European Commission is currently revising
their guidelines in conjunction with the European Society of
Radiology.
Ideal integrated diagnostic algorithms will depend on the
acquisition of sequential information for more accurate and
specific diagnoses. Algorithms should start with the least
expensive tests that will narrow down the possibilities and
effectively increase the positive predictive value of subse-
quent tests [36]. Each test in a diagnostic algorithm should
break the tested population into smaller subpopulations with
specific phenotypes, or sets of observable traits, for which
the associated risks of disease are better defined. As medical
knowledge increases, so, too, do the numbers of disease
phenotypes—and genotypes—that must be ruled out or in;
this adds difficulty to the diagnostic process but makes
patient care more efficient by helping to determine which
treatment, if any, is likely to work. For example, the number
of types of lymphoma recognised has exploded from 5 to
53, and the type drives the choice of treatment [36].
Once developed, application of integrated diagnostic
algorithms should result in faster diagnoses, with greater
precision and less cost. As an example, we can consider
the algorithm for the diagnosis of patients presenting to
emergency departments with chest pain. In the current stan-
dard of care in the USA, all patients with suspected acute
coronary syndrome (ACS) are first given an electrocardio-
gram to detect arrhythmias and a troponin assay. Those with
ST segment elevation myocardial infarction (STEMI) are
immediately recognised and treated. But the majority of
patients, who do not have STEMI, are given presumptive
therapy with aspirin, oxygen, and β-blockers and are eval-
uated with serial electrocardiograms and cardiac enzyme
assays over a period of 8 to 12 h. If troponin levels do not
rise, rest and/or stress-imaging studies are performed to rule
out ischaemia. While this process has lowered missed diag-
noses of ACS, it is both time-consuming and expensive
(emergency evaluations for acute chest pain cost approxi-
mately $10 billion annually in the USA) [66].
However, this diagnostic algorithm for suspected ACS
may soon change as recent studies have explored the inte-
gration of non-invasive coronary CT angiography (CCTA)
into the algorithm to rule out ACS or severe stenosis early
on in the work-up, for example, after just one or two enzyme
assays [66, 67]. Even though CT examinations are expen-
sive, these studies have found that the use of CCTA is cost
effective because it reduces time to diagnosis and the num-
ber of hospital admissions. With CCTA, the median time to
diagnosis fell from 15 h to just 3.4 h in one study [66]. The
main strength of CCTA is its high negative predictive value,
which allowed as many as 67 % of those imaged to be
discharged while the remainder were divided into distinct
higher-risk categories suitable for further testing [66, 67].
Moreover, CCTA lowers hospital readmission rates without
causing adverse cardiovascular events in the near or mid
term, with readmission rates falling from 9 % to 1 % in one
study [67].
In the development of new integrated diagnostic algo-
rithms, the sequence of tests should be determined by mul-
tidisciplinary teams of physicians that include radiologists
and other specialists that care for particular patient popula-
tions. Determining the optimal use of diagnostic tests will
require heavy use of IT to calculate the probabilities and
discern linkages between data and disease, because the
complexity of the data precludes depending solely on intu-
ition and experience. It will also be essential to be able to
share information among disciplines, which will require the
adoption of standard nomenclature, using ontologies such as
SNOMED [64] and RADLEX [68]. Adopting a common
language will be a major hurdle but will make it possible to
use natural language processing to extract diagnostic
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phenotypes from unstructured reports [62], better under-
stand the pattern and progress of disease, and facilitate the
development of reproducible algorithms, decision trees, and
data assembly tools to integrate data from diverse sources.
In order to be effective in a world of integrated diagnos-
tics, radiologists will need to be able to move beyond their
analogue world of qualitative interpretation of radiological
signs, non-specific tissue contrast, and free text reports—
descriptive findings that may not interpret the study in light
of the clinical setting. Radiologists must think in terms of
quantitative data on imaging biomarkers as well as quanti-
tative data from pathology tests and clinical information.
Such quantitative data will be necessary to develop and
apply diagnostic algorithms with decision support tools.
The Quantitative Imaging Biomarker Alliance (QIBA),
launched in 2007 and whose membership includes radiolo-
gy researchers, industry, and government regulators, has
made some progress in regard to the development of quan-
titative imaging biomarkers, the development of uniform
protocols for imaging in clinical trials, and education at
society meetings [69, 70].
Achieving reliable, reproducible, and comparable quan-
titative imaging results amongst different institutions will
require standardization of imaging equipment across ven-
dors, standardization of imaging protocols, and correlations
with clinically meaningful metrics. Equipment manufac-
turers must be convinced of the necessity to standardize.
Radiology societies will need to educate their memberships
by including quantitative imaging presentations at national
meetings, as well as exhibits related to software that can be
incorporated into routine radiologic practice. Moreover, im-
aging biomarkers will need to be accepted by regulators in
order to foster their acceptance. We can anticipate resis-
tance, both from vendors who want to be seen as different
from their competitors and from radiologists who fear losing
value due to automation [70]. Most importantly, a major
effort will be necessary to set up standardized reporting for
all clinical fields of imaging and to train radiologists to
provide clinicians with standardised reports.
More radiology training and subspecialisation will also
be helpful in a world of integrated diagnostics. Benefits of
subspecialisation include higher level of expertise, higher
quality of patient services, improved efficiency, and im-
proved interaction and common language with other clini-
cians. Subspecialization improves the standing of radiology
as a specialty, enriches radiologists’ armamentarium in turf
battles, provides a stronger basis for clinical research, and
supports recruitment of students into radiology. However,
subspecialization needs to evolve from one-dimensional
organ/system-based models to three-dimensional patient-
centred matrix models that consider the disease and the
presenting clinical problem [71]. Training models need to
include complex tasks for radiologists, including tumour
boards, interdisciplinary conferences, and new models of
patient-centred care in oncology, diabetes, and metabolic
disorders, among others.
Revised subspecialty categorisation is also needed in
order to reflect the continuing evolution of radiology and
the development of hybrid imaging methods, such as PET/
CT and MR/PET and novel molecular tracers, and to ac-
knowledge that no one can master the entire field of imaging
[70]. Hybrid imaging technologies require physician exper-
tise in both functional and anatomic imaging and are driving
the convergence of radiology and nuclear medicine into the
new subspecialty of molecular imaging [72]. In Europe, the
European Association of Nuclear Medicine and the
European Society of Radiology have recognised the impor-
tance of coordinating working practices between radiology
and nuclear medicine for multimodal imaging [73]. In the
USA, the ACR and the Society of Nuclear Medicine con-
vened the Task Force on Nuclear Medicine Training to
define the issues and develop recommendations for resident
training [74]. Despite these efforts, it must be recognised
that there are a number of institutional barriers that need to
be overcome before molecular imaging becomes a subspe-
cialty, such as regulation review requirements, reimburse-
ment, hospital organization, and limitations in the
development and cost-efficient supply of novel molecular
tracers [73].
Professionally, becoming members of integrated diagnos-
tic and therapeutic teams will benefit radiologists who, in
present practice, are nearly invisible, leaving the public
largely ignorant of what they do [22, 75]. Radiologists must
become more visible, remain physicians, and go for the
diagnostic driver’s seat. The current radiology business
model is a professional service that is being deconstructed
into components by virtue of digitalization, with each com-
ponent being transformed by computation and by bioinfor-
matics. It has been suggested that a continuation of the
present emphasis on image interpretation and reporting,
rather than consultation and problem-solving, runs the risk
that the radiology profession will become marginalized and
commoditized. On the other hand, applying knowledge and
wisdom to consultations with referring physicians is unlike-
ly ever to be commoditised [76]. Therefore, in order to
retain their standing, radiologists have to recognize that
radiology is more than just imaging and engage more di-
rectly with both patients and referring physicians.
By becoming more visible to patients and more substan-
tively involved in patients’ medical care as active team mem-
bers, radiologists will be better prepared for the anticipated
future, when they will be actively involved in selecting the
sequence of diagnostic procedures. Ultimately, they may even
become leaders and doorkeepers routinely in contact with
patients [77] in departments of diagnostic medicine that in-
clude laboratory science, pathology, and radiology.
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